Literature DB >> 24178636

Effects of branched-chain amino acids on plasma amino acids in amyotrophic lateral sclerosis.

O Gredal1, S E Møller.   

Abstract

Although the cause of amyotrophic lateral sclerosis (ALS) remains unknown, biological findings suggest that the excitatory amino acid glutamate contributes to the pathogenesis of ALS. In previous studies of ALS, the therapeutic effect of the branched-chain amino acids (BCAAs) leucine, valine and isoleucine has been evaluated. The present study aimed at investigating the acute effect of BCAAs on plasma glutamate levels in ALS patients. Following two oral doses of BCAAs, significantly increased plasma levels were seen for valine (500%), isoleucine (1,377%) and leucine (927%), however the plasma level of glutamate was not affected. The plasma level of several other amino acids (tryptophan, tyrosine, phenylalanine and methionine) were found decreased after oral BCAAs, which may indicate a diminution in the rate of degradation of muscle protein and/or an increase in tissue disposal of amino acids.

Entities:  

Year:  1996        PMID: 24178636     DOI: 10.1007/BF00805719

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  22 in total

Review 1.  Excitotoxins and amyotrophic lateral sclerosis.

Authors:  T L Munsat; D Hollander
Journal:  Therapie       Date:  1990 May-Jun       Impact factor: 2.070

Review 2.  Glutamate neurotoxicity and diseases of the nervous system.

Authors:  D W Choi
Journal:  Neuron       Date:  1988-10       Impact factor: 17.173

3.  Branched-chain aminoacids in amyotrophic lateral sclerosis.

Authors: 
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

4.  Quantification of physiological amino acids by gradient ion-exchange high-performance liquid chromatography.

Authors:  S E Møller
Journal:  J Chromatogr       Date:  1993-04-02

5.  Effect of branched-chain amino acids on glutamate metabolism in amyotrophic lateral sclerosis.

Authors:  O Gredal; S E Møller
Journal:  J Neurol Sci       Date:  1995-03       Impact factor: 3.181

6.  Prospective study on the efficacy of branched-chain amino acids in septic patients.

Authors:  F J Jiménez Jiménez; C Ortiz Leyba; S Morales Ménedez; M Barros Pérez; J Muñoz García
Journal:  JPEN J Parenter Enteral Nutr       Date:  1991 May-Jun       Impact factor: 4.016

7.  Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study.

Authors:  M Plauth; E H Egberts; W Hamster; M Török; P H Müller; O Brand; P Fürst; W Dölle
Journal:  J Hepatol       Date:  1993-03       Impact factor: 25.083

8.  Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle.

Authors:  E Blomstrand; E A Newsholme
Journal:  Acta Physiol Scand       Date:  1992-11

9.  Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis.

Authors:  A Plaitakis; J Smith; J Mandeli; M D Yahr
Journal:  Lancet       Date:  1988-05-07       Impact factor: 79.321

10.  Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid.

Authors:  T L Perry; C Krieger; S Hansen; A Eisen
Journal:  Ann Neurol       Date:  1990-07       Impact factor: 10.422

View more
  2 in total

1.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

2.  Altered Metabolic Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures.

Authors:  Gabriel N Valbuena; Massimo Tortarolo; Caterina Bendotti; Lavinia Cantoni; Hector C Keun
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.